title: CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
abstract: Considerable effort has been put into targeting tumors through therapeutic vaccination using dendritic cell-, DNA-, protein-, or peptide-based vaccines. Purified peptides and proteins are generally not immunogenic and need to be administered with an adjuvant that will trigger an appropriate immune response. Safe adjuvants that favor induction of tumor reactive CD8(+) T cells with the capacity to directly kill tumor cells are therefore a high priority. We have previously reported on the effect and mechanism of a cationic adjuvant formulation, CAF01, which incorporates synthetic mycobacterial cord factor and primes protective Th1, Th17, and antibody responses in animal models of bacterial, viral, and parasitic infections. The CAF01 adjuvant is currently in clinical trial. Using CAF01 as a backbone, we recently demonstrated that incorporating the TLR3 ligand polyinosinic/polycytidylic acid [poly(I:C)] primes CD8(+) T cells specific to the SIINFEKL epitope of the model antigen ovalbumin. In the present study, we demonstrate that CAF01/poly(I:C), termed cationic adjuvant formulation 05 or CAF05, can induce CD8(+) T cells that efficiently lyse target cells and significantly reduce tumor growth in two different mouse tumor models: lung B16-OVA melanoma expressing ovalbumin and the self-antigen TRP2, and subcutaneous TC-1 tumors expressing the human papillomavirus-16 protein E7.
authors.affiliation: Infectious Disease Immunology, Statens Serum Institut, Building 81/306, Copenhagen S, Denmark. joa@ssi.dk
authors.forename: Jon
authors.initials: J
authors.lastname: Hansen
authors.forename: Thomas
authors.initials: T
authors.lastname: Lindenstrøm
authors.forename: Julie
authors.initials: J
authors.lastname: Lindberg-Levin
authors.forename: Claus
authors.initials: C
authors.lastname: Aagaard
authors.forename: Peter
authors.initials: P
authors.lastname: Andersen
authors.forename: Else Marie
authors.initials: EM
authors.lastname: Agger
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002412:Cations; D005260:Female; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D050725:Papillomavirus E7 Proteins / Q000276:immunology; D011070:Poly I-C / Q000008:administration & dosage / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D047368:Tumor Burden / Q000187:drug effects* / Q000276:immunology; D014611:Vaccination; D023041:Xenograft Model Antitumor Assays
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D002412:Cations; D008081:Liposomes; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D011070:Poly I-C
references.citation: J Infect Dis. 1997 Apr;175(4):927-31
references.pmid: 9086151
references.citation: Eur J Immunol. 2006 Dec;36(12):3346-55
references.pmid: 17109467
references.citation: Clin Exp Immunol. 1994 May;96(2):356-63
references.pmid: 8187345
references.citation: Cancer Res. 2010 Feb 1;70(3):875-82
references.pmid: 20103634
references.citation: J Immunol. 2010 Mar 15;184(6):2756-60
references.pmid: 20164423
references.citation: Immunol Rev. 2011 Jan;239(1):27-44
references.pmid: 21198663
references.citation: Nat Immunol. 2000 Dec;1(6):515-20
references.pmid: 11101874
references.citation: Biochim Biophys Acta. 2005 Dec 10;1718(1-2):22-31
references.pmid: 16321607
references.citation: J Clin Invest. 2010 Feb;120(2):607-16
references.pmid: 20101095
references.citation: Eur J Immunol. 2006 Dec;36(12):3371-80
references.pmid: 17109465
references.citation: PLoS One. 2009 Jun 03;4(6):e5771
references.pmid: 19492047
references.citation: PLoS One. 2010 Aug 10;5(8):e11995
references.pmid: 20706632
references.citation: Immunol Cell Biol. 2004 Oct;82(5):488-96
references.pmid: 15479434
references.citation: J Immunol. 2005 Nov 1;175(9):6169-76
references.pmid: 16237114
references.citation: Annu Rev Immunol. 2006;24:99-146
references.pmid: 16551245
references.citation: J Infect Dis. 2008 Sep 1;198(5):758-67
references.pmid: 18652549
references.citation: Cytokine Growth Factor Rev. 2008 Feb;19(1):33-40
references.pmid: 18068417
references.citation: Eur J Immunol. 2008 May;38(5):1247-56
references.pmid: 18412160
references.citation: PLoS One. 2008 Sep 08;3(9):e3116
references.pmid: 18776936
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: J Exp Med. 2009 Jan 16;206(1):89-97
references.pmid: 19139169
references.citation: Cancer Sci. 2004 Sep;95(9):697-703
references.pmid: 15471553
references.citation: Immunology. 2007 Jun;121(2):216-26
references.pmid: 17302734
references.citation: J Control Release. 2010 Mar 3;142(2):180-6
references.pmid: 19874860
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
references.pmid: 16344461
references.citation: PLoS One. 2008 Jul 09;3(7):e2636
references.pmid: 18612426
references.citation: J Biomed Biotechnol. 2010;2010:237623
references.pmid: 20617155
references.citation: Vaccine. 2011 Mar 3;29(11):2100-9
references.pmid: 21256189
references.citation: Annu Rev Immunol. 2001;19:683-765
references.pmid: 11244051
references.citation: Immunity. 2009 Nov 20;31(5):787-98
references.pmid: 19879162
references.citation: J Control Release. 2011 Mar 30;150(3):307-17
references.pmid: 21111765
references.citation: Infect Immun. 2004 Mar;72(3):1608-17
references.pmid: 14977968
references.citation: J Immunol. 2006 Jun 15;176(12):7335-45
references.pmid: 16751377
references.citation: J Exp Med. 2009 Aug 3;206(8):1717-25
references.pmid: 19581407
references.citation: Vaccine. 2011 Sep 16;29(40):7067-74
references.pmid: 21767590